Published in Int J Neuropsychopharmacol on October 31, 2014
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther (2002) 3.67
Atypical antipsychotics: mechanism of action. Can J Psychiatry (2002) 2.91
Distinct functions of the two isoforms of dopamine D2 receptors. Nature (2000) 2.83
GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci (2007) 2.35
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol (2002) 2.15
Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology (2006) 1.61
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 1.60
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology (2002) 1.35
Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci (2012) 1.29
Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci (2001) 1.26
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des (2010) 1.24
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther (1995) 1.17
Structural determinants of sigma receptor affinity. Mol Pharmacol (1987) 1.07
Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry (1998) 1.01
An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry (2005) 1.00
Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One (2013) 0.97
Partial dopamine agonists in the treatment of psychosis. J Neural Transm (Vienna) (2002) 0.94
Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol (1989) 0.92
Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol (1987) 0.92
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol (2009) 0.92
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) (2007) 0.91
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol (2005) 0.91
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol (2011) 0.90
Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors. Eur J Pharmacol (2011) 0.87
Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm (1985) 0.83
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol (2009) 0.83
Agonist-specific voltage sensitivity at the dopamine D2S receptor--molecular determinants and relevance to therapeutic ligands. Neuropharmacology (2011) 0.83
Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83
Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol (2013) 0.83
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol (2010) 0.82
Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats. J Neural Transm (Vienna) (2007) 0.81
D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr Top Med Chem (2008) 0.80
R(+)-8-OH-DPAT, a selective 5-HT(1A) receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex. Brain Res (2000) 0.77
The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum. Behav Brain Res (1996) 0.77